Skip to main content
SpringerLink
Log in

Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment

  • Use of Biomarkers to Select the Target Population for Clinical Trials
  • Published:
JNHA - The Journal of Nutrition, Health and Aging

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Visser, PJ and FR Verhey, Mild cognitive impairment as predictor for Alzheimer’s disease in clinical practice: effect of age and diagnostic criteria. Psychol Med 2008; 38: 113–122.

    Article  PubMed  CAS  Google Scholar 

  2. Jelic, V, M Kivipelto, and B Winblad, Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006; 77: 429–438.

    Article  PubMed  CAS  Google Scholar 

  3. Visser, PJ, P Scheltens, and FR Verhey, Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2005; 76: 1348–1354.

    Article  PubMed  CAS  Google Scholar 

  4. Salloway, S, et al., Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63: 651–657.

    PubMed  CAS  Google Scholar 

  5. Visser, PJ, et al., Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; 67: 1201–1207.

    Article  PubMed  Google Scholar 

  6. Fox, NC, et al., Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358: 201–205.

    Article  PubMed  CAS  Google Scholar 

  7. O’Brien, JT, et al., Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001; 56: 1386–1388.

    PubMed  Google Scholar 

  8. Jack, CR, Jr., et al., Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008; 70: 1740–1752.

    Article  PubMed  Google Scholar 

  9. Visser, PJ, Diagnosis of predementia AD in a clinical setting, in Alzheimer’s disease. A physician’s guide to practical management. B. Zoeller-Richter, Editor. 2003, Humana Press: New Yersey. p. 157–164.

    Google Scholar 

  10. Nordberg, A, PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 2004; 3: 519–527.

    Article  PubMed  CAS  Google Scholar 

  11. Blennow, K and H Hampel, CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2: 605–613.

    Article  PubMed  CAS  Google Scholar 

  12. Koivunen, J, et al., PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378–83.

    Article  PubMed  CAS  Google Scholar 

  13. Forsberg, A, et al., PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456–1465.

    Article  PubMed  CAS  Google Scholar 

  14. Alexander, GE, et al., Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies. Am J Psychiatry 2002; 159: 738–745.

    Article  PubMed  Google Scholar 

  15. Zetterberg, H, et al., Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis 2007; 12: 255–260.

    PubMed  CAS  Google Scholar 

  16. Brys, M, et al., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2007.

  17. Andersson, C, et al., Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008; 29: 1466–1473.

    Article  PubMed  CAS  Google Scholar 

  18. Engler, H, et al., Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006; 129: 2856–2866.

    Article  PubMed  Google Scholar 

  19. Busse, A, et al., Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176–2185.

    Article  PubMed  CAS  Google Scholar 

  20. Winblad, B, et al., Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024–2035.

    Article  PubMed  CAS  Google Scholar 

  21. Feldman, HH, et al., Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501–512.

    Article  PubMed  CAS  Google Scholar 

  22. Petersen, RC, et al., Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379–2388.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson, SA and VF Simmon, Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci 2002; 19: 197–200.

    Article  PubMed  CAS  Google Scholar 

  24. Thal, LJ, et al., A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology 2005.

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Maastricht, PO Box 616, 6200 MD, Maastricht, The Netherlands

    P. J. Visser

  2. Department of Neurology, VUMC, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    P. J. Visser

Authors
  1. P. J. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. Visser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Visser, P.J. Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment. J Nutr Health Aging 13, 344–345 (2009). https://doi.org/10.1007/s12603-009-0037-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12603-009-0037-6

Keywords

Search

Navigation